Quarterly report pursuant to Section 13 or 15(d)

NATURE OF BUSINESS AND ORGANIZATION (Details)

v3.23.2
NATURE OF BUSINESS AND ORGANIZATION (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Sep. 30, 2022
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Accumulated deficit   $ 196,301,532       $ 196,301,532   $ 179,499,043
Net loss   8,221,222 $ 8,581,267 $ 7,435,043 $ 6,139,797 16,802,489 $ 13,574,840  
Fixed asset impairment charges           0    
Uninsured cash balances   4,653,000       4,653,000   $ 19,400,000
Reduction in research and development           647,000    
Cancer treatment research award through the National Cancer Institute (NCI)                
Grant amount   2,000,000.0       $ 2,000,000.0    
Grant period           3 years    
Grant received $ 1,980,000 $ 241,000            
Leasehold improvements                
Property and equipment useful lives   64 months       64 months    
Minimum                
Property and equipment useful lives   3 years       3 years    
Share-based compensation expiration period           1 year    
Maximum                
Property and equipment useful lives   10 years       10 years    
Share-based compensation expiration period           3 years